Parallel review in Panama and El Salvador: cutting sequential clinical trial backlogs

Sequential startup is the silent killer of early-phase calendars. Ethics finishes. Then the ministry opens the protocol. Then someone asks for a Spanish annex you already had. Six to twelve months disappear before first-patient-in.

I am Julio Martinez-Clark, CEO of bioaccess®. Panama and El Salvador sit in the second rapid-startup archetype: parallel review. Centralized authorities evaluate protocols at the same time as ethics committees. You still clear both gates. You stop waiting for them in series.

This is Part 2 of the Latin America rapid-startup archetypes series. Part 1 covered pure ethics committee approval in Chile and Costa Rica. Part 3 is the comparative selection matrix. Corridor context: fast-track FIH corridor. Not legal advice — confirm the pathway on filing day.

The archetype in one sentence

Parallel review means the regulator and the ethics body work the same protocol package concurrently, so the traditional 6–12 month sequential backlog never becomes your critical path.

Sponsors who need a national authority’s validation on the docket — without paying for that validation in serial months — belong here.

Panama: Decreto Ejecutivo 21/2026, Art. 91, Type II CBIs, RESEGIS

On 23 April 2026 Panama published Decreto Ejecutivo No. 21 (Gaceta Oficial No. 30510-C), implementing Titles III and IV of Ley 84 of 14 May 2019. For startup design, three pieces matter more than the rest of the decree:

• RESEGIS — MINSA’s web platform for registro y seguimiento of health-research projects. Studies register before execution; the public docket is real, not folklore.
• CNBI-accredited Type II CBIs — clinical trials go to Type II Comités de Bioética de la Investigación accredited by the national committee (CNBI). Ordinary ethics clocks are defined in the decree (including a 20-business-day ordinary review frame for complete files).
• Artículo 91 parallel evaluation — for the high-risk / clinical-trial line, MINSA’s evaluation and the accredited Type II CBI review run simultaneously. The ministry review does not freeze the ethics clock.

Operationally, that is why Panama startup compresses into roughly 30–45 days when the Spanish file is complete and the Type II committee is correctly selected. Parallelism is the design. Incomplete dossiers are still the failure mode.

Operator checklist for Panama:

1. Confirm the ethics destination is a CNBI-accredited Type II CBI. Type I is the wrong lane for interventional trials.
2. Register the project in RESEGIS on the decree’s timeline — do not treat ethics approval as a substitute for registration.
3. Submit a Spanish package that both MINSA and the CBI can review without translation theater: protocol, IB, consent, insurance, investigator and site docs.
4. Plan import / pharmacy (including DNFD touchpoints where the product path requires them) as logistics that ride the RESEGIS + ethics + authorization chain — not as a surprise third sequential science review.
5. Read the public RESEGIS list if you want proof the country is not opaque. The docket is an Excel-shaped reality, not a black box.

Deeper Panama notes already live on the site: Decreto 21 of 2026 explained, CNBI / Type II procedure checklist, RESEGIS public trial docket, and functional animal studies vs Decreto 21.

El Salvador: SRS-CNEIS-ES unified digital submission

El Salvador’s parallel model is digital by design. Sponsors submit through the SRS-CNEIS-ES platform. One structured submission feeds both:

• SRS — Superintendencia de Regulación Sanitaria (the national sanitary regulator; successor posture to the former DNM for this work), and
• CNEIS — Comité Nacional de Ética de la Investigación en Salud.

SRS and CNEIS review concurrently. You are not waiting for ethics to finish before the regulator opens the file, or the reverse. CNEIS pleno review commonly runs on a 4–6 week cadence; overall clearance for a complete international protocol typically lands in 30–60 days.

That combination — one ethics body with national authority for international pharmaceutical / clinical protocols, one regulator, one digital submission — is why sponsors who want authority validation without sequential delay keep El Salvador on the short list.

Operator checklist for El Salvador:

1. Create the SRS-CNEIS-ES account and roles before you promise a board date. Platform access is part of the critical path.
2. Upload a complete package on the first pass. Parallel review punishes incompleteness twice — both desks ask at once.
3. Track status inside the platform. Do not invent a parallel email channel that splits the audit trail.
4. Separate trial authorization from commercial registro thinking. A FIH clearance is not a marketing authorization; keep the investigational file off the commercial hold pattern.
5. Model hospital fees and site activation as a second workstream. Regulatory parallelism does not auto-complete contracting.

Related El Salvador posts: FIH step-by-step guide, CNEIS/SRS trial authorization vs registro.

Parallel review vs pure ethics — choose on purpose

Parallel review is not “better” than Chile/Costa Rica’s pure-ethics archetype. It is a different product.

• Buy parallel review when your investors, notified body, or internal QA want a national regulator’s concurrent evaluation on the protocol — and you refuse to pay for that with a sequential backlog.
• Buy pure ethics when the CEC letter is the authorization you need to open sites, and ministry involvement is import / registry logistics rather than protocol science.

Confusing the two produces bad decks: Chile sold as “ministry co-approval,” or Panama sold as “ethics only.” Neither story survives diligence.

What still kills the 30–45 / 30–60 day windows

Parallelism removes waiting between desks. It does not remove:

• Incomplete Spanish informed consent or IB
• Wrong ethics destination (Panama Type I vs Type II)
• Missing insurance or site letters
• Import / customs readiness that starts the week you hoped to screen
• Honest recruitment math in smaller populations

bioaccess® will tell you the clock on the statute and the clock on your file. They are not the same number until the dossier is complete.

Submission logistics that make parallelism real

Parallel review fails in the same place sequential review fails: the first incomplete upload. The difference is you learn it from two desks at once.

For Panama, treat RESEGIS registration, Type II CBI submission, and MINSA evaluation as one workstream with shared Spanish source files. Assign a single document controller. Version the protocol once. Do not let the ethics PDF and the ministry PDF drift by a forgotten amendment.

For El Salvador, the SRS-CNEIS-ES platform is the workstream. Role setup, document taxonomy, and in-platform responses are part of Good Clinical Practice hygiene, not IT busywork. If your team answers SRS questions by WhatsApp and CNEIS questions by email, you have rebuilt sequential chaos on top of a parallel system.

Import readiness belongs on the same Gantt row as review. A 35-day clearance with a device still on a US loading dock is not a 35-day path to first-patient-in. bioaccess® sequences customs, temperature control, and site pharmacy qualification against the expected clearance week — not against hope.

Audience fit

This archetype is for sponsors seeking regulatory-authority validation without sequential approval delays — Clinical Operations VPs and Regulatory Affairs leads who must show a ministry or superintendencia touch on the protocol while still protecting a FIH calendar measured in weeks.

Next: Part 3 — comparative framework and selection matrix across all four countries.

Talk with bioaccess® when you need a Panama RESEGIS + Type II file or an El Salvador SRS-CNEIS-ES package built for concurrent review — the First-in-Human CRO posture we have held in Latin America since 2010.